{"title":"A compendium of noncoding RNAs as biomarkers in Type 2 Diabetes Mellitus","authors":"Manjusha Sita Akella, Angel Mendonca, Thanikes Manikandan, Dhananjay Sateesh, Akshitha Rajesh Swaminathan, Disha Parameshwaran, Manishika Gupta, Sujatha Sundaresan","doi":"10.1016/j.jpbao.2025.100057","DOIUrl":null,"url":null,"abstract":"<div><div>Diabetes Mellitus (DM) is among the most widespread multifactorial disorders worldwide, defined by increased plasma glucose levels. Type 2 Diabetes Mellitus (T2DM) is the most prevalent and common form of diabetes mellitus. T2DM is a metabolic condition characterized by abnormal blood glucose levels, insulin resistance in target tissues, and a reduced mass and function of islet β cells. Highlighting the significance of investigating new biomarkers, particularly during the initial stages of development, noncoding RNAs (ncRNAs) have been identified as valuable resources for T2DM. NcRNAs are a class of RNAs found in humans that play significant roles in epigenetics and in regulating post-transcriptional gene expression. Since they function as regulatory molecules, upon base pairing with the mRNA, they exhibit post-transcriptional alterations in the signaling cascade within the cells by regulating the expression of multiple targets simultaneously. Small non-coding RNAs (sncRNAs) and long non-coding RNAs (lncRNAs) are the two primary categories of non-coding RNAs. Several studies have shown that sncRNAs and lncRNAs have evolved as potential biomarkers in T2DM. This review focuses on non-coding RNAs as biomarkers for T2DM and their role in preventing chronic complications.</div></div>","PeriodicalId":100822,"journal":{"name":"Journal of Pharmaceutical and Biomedical Analysis Open","volume":"5 ","pages":"Article 100057"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical and Biomedical Analysis Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949771X25000088","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Diabetes Mellitus (DM) is among the most widespread multifactorial disorders worldwide, defined by increased plasma glucose levels. Type 2 Diabetes Mellitus (T2DM) is the most prevalent and common form of diabetes mellitus. T2DM is a metabolic condition characterized by abnormal blood glucose levels, insulin resistance in target tissues, and a reduced mass and function of islet β cells. Highlighting the significance of investigating new biomarkers, particularly during the initial stages of development, noncoding RNAs (ncRNAs) have been identified as valuable resources for T2DM. NcRNAs are a class of RNAs found in humans that play significant roles in epigenetics and in regulating post-transcriptional gene expression. Since they function as regulatory molecules, upon base pairing with the mRNA, they exhibit post-transcriptional alterations in the signaling cascade within the cells by regulating the expression of multiple targets simultaneously. Small non-coding RNAs (sncRNAs) and long non-coding RNAs (lncRNAs) are the two primary categories of non-coding RNAs. Several studies have shown that sncRNAs and lncRNAs have evolved as potential biomarkers in T2DM. This review focuses on non-coding RNAs as biomarkers for T2DM and their role in preventing chronic complications.